Pfizer's Guidance Raise Rests on Eliquis' 25% Surge — a Price-Cut Harvest With a Calendar Attached

Pfizer reported third-quarter 2026 revenue of $16.58 billion, $71 million below the $16.65 billion booked a year earlier. The top line was flat as reported and roughly flat operationally; revenue excluding COVID-19 products grew 7%. Adjusted diluted earnings came in at $0.87 against a $0.73 consensus, while reported diluted earnings were $0.56 after $742 million of restructuring and acquisition-related charges. Rested on one product whose US exclusivity ends on April 1, 2028, the quarter was carried by three franchises: anticoagulants, Seagen-derived oncology, and the COVID base finally rolling off.

The arithmetic matters more than the headline. Eliquis supplied $513 million of incremental sales, 64% of what Paxlovid gave back in a single quarter, and Comirnaty and Prevnar took another $519 million out. Launched and acquired products grew 32% operationally, acquired products 37%, and the legacy Seagen portfolio39% in the US — real, compounding growth — but it arrived in a quarter where the reported top line did not move.

Bristol-Myers Squibb's own filing explains the mechanism in one sentence: the company reduced the US list price for Eliquis in 2026, which lowered rebates and produced higher realized average net selling prices. Volume is not the story — price is. Because rebates are struck against list, cutting the list price shrinks the base on which they are calculated, so the net revenue booked per script rises even as the invoice price falls. Cutting the list price lifted the revenue both partners report, and the effect lands in the year the Medicare maximum fair price took effect.

The alliance structure is legible in the two filings. Pfizer's 10-K describes equal sharing of Eliquis profits and losses, Pfizer funding 50% to 60% of development costs, and — in certain smaller markets where Pfizer holds full commercialization rights — Bristol-Myers Squibb supplying the product at cost plus a percentage of net sales. That is why Pfizer's $1,808 million US line sits at 49.5% of the partner's $3,653 million. One product, two sets of books, one earnings event.

Two conclusions follow. First, the mechanism is not repeatable: Medicare's maximum fair price of $231 per 30-day supply is 56% below the $521 2023 list price and is the floor the Part D book is priced at, so the rebate headroom that produced 2026's net-price lift has already been spent. Second, it is not shipments pulled forward: inventory fell to $9.95 billion at June 28, 2026 from $10.65 billion at December 31, 2025 while revenue ran above the prior year. Hot revenue with shrinking inventory points to mix and price, not to channel loading — which is worse for 2027, because a timing benefit unwinds inside a year while a rebate reset does not come back.

Pfizer's FY2025 Form 10-K dates the end of the party in the patent table. The US basic product patent for apixaban expires in 2027; settled generic filers are permitted to launch on April 1, 2028; and three remaining filers, having lost to Pfizer, are blocked until the formulation patent expires in 2031. The tail risk is dated too — if the formulation patent is held invalid or not infringed through appeal, settled generics could launch as early as November 21, 2026, and if both patents fall, they could launch immediately. The 2028 problem carries an option that expires this year.

The durable half of the story faces its own statutory reset. Pfizer's 10-K records that CMS selected 15 Part D drugs for negotiated prices effective January 1, 2027 — including Ibrance and Xtandi — and on January 27, 2026 selected another 15 for January 1, 2028, including Xeljanz. In the third quarter, Ibrance was $1,082 million, Xtandi $541 million, Padcev $720 million and Lorbrena $387 million, with oncology overall at $4,327 million, up 10%. The portfolio meant to replace a $10 billion Eliquis line gets statutory price cuts six months later, so a 2027 case built on oncology has to survive an Ibrance and Xtandi repricing nobody has quantified yet.

That is the recalibration the print forces. Investors cannot extrapolate Eliquis into 2027 and call the oncology ramp a hedge, because the hedge is itself scheduled for statutory repricing. The honest 2027 model has three moving parts: a protected-but-expiring anticoagulant, an oncology portfolio whose growth partly precedes its own price cut, and a cost program whose savings only begin when the revenue steps down.

Upstream, the Eliquis harvest accrues to the same partner on both sides of the alliance. Bristol-Myers Squibb manufactures and supplies Eliquis to Pfizer in certain smaller markets at cost plus a percentage of net sales, and the two split US profits equally — so every incremental Eliquis script is, in effect, half a Pfizer problem and half a Bristol-Myers Squibb problem, with the cost side settling upstream at the partner's plants.

Downstream is where the reset is least visible and least damaging. Pfizer's US brands move through McKesson, Cencora and Cardinal Health. The Medicare cut from a $521 list price to a $231 negotiated price already shrank the branded dollar value moving through that channel, and generic apixaban from April 1, 2028 converts high-price, low-volume scripts into low-price, high-volume ones — fewer revenue dollars per prescription for the wholesalers. Both McKesson and Cencora also document the negotiation calendar directly: maximum fair prices for the 2027 Part D cycle must be published by November 30, 2026 and take effect January 1, 2027, and the third round takes effect January 1, 2028.

At the November 3, 2026 close, Pfizer's market capitalization of $174.8 billion put the shares near10 times the $3.00 midpoint of the raised 2026 adjusted EPS guidance, on about 3.7 times trailing sales, a 6.3% free cash flow yield and 4.6 times net debt to EBITDA. Trailing operating cash flow of $13.4 billion funds $11.0 billion of free cash flow against $9.8 billion of dividends, $6.9 billion of acquisitions and $2.8 billion of interest; net debt stood at $62.2 billion and $3.3 billion of buyback authorization remained on the day of the print. The balance sheet buys time for the cliff, not immunity from it, and a new chief financial officer, Cecile Guegan, inherits both the harvest and the repayment schedule.

Read that table as a verdict on the print. Pfizer and Bristol-Myers Squibb — the two halves of the same cliff — already trade at 3.3 to 3.7 times sales with 6% to 7% free cash flow yields, cheaper than Merck & Co. and far cheaper than Johnson & Johnson at 6 to 7 times sales. The market has discounted a good deal of the melt before the guidance raise. A raise built on a price reset inside a protected window does not move that curve; it only changes which quarter the curve is measured from.